Cytori (CYTX) Receives 510(k) Clearance for Puregraft(R) from FDA

Article Stock Quotes (1) Comments (0)

Cytori (NASDAQ: CYTX) has received 510(k) clearance from the U.S. FDA for the Puregraft 850 System for body contouring using a patient's own fat. The Puregraft 850 product line extension provides optimized and sterile processing of up to 850 mL of tissue, a significantly larger volume than the Puregraft 250, which received a 510(k) in January 2010. Larger tissue volumes expand the range of soft tissue procedures for which the product line may be used.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Merck (MRK) Says Efficacy Not Achieved in Preladenant Phase 3s; Will Discontinue
• Janssen Pharma (JNJ) Plans Slew of Filing, Extension Submissions by FY17
• Sprint (S), SoftBank Receive Final State Regulatory Approval in Proposed Deal

Create E-mail Alert Related Categories

Corporate News, FDA

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?